Imunon, Inc.

Please stand by. Good morning. My name is Nick and I will be your operator today. At this time, I would like to welcome you to the Immunon first quarter 2024 financial results conference call. All lines have been placed on mute to prevent any background noise. Following the speaker's prepared remarks, there will be a question and answer session. You may press star 1 on your phone to ask a question at that time. Please keep in mind, if you are using a speakerphone, you must release your mute function to allow the signal to reach our equipment. Again, that's star 1 to ask a question during the Q&A session. I would now like to turn the call over to Kim Golodets. Please go ahead.

Thank you, and good morning, everyone. This is Kim Golodets with LHA. Welcome to WIMUNO's first quarter 2024 financial results and business update conference call. During today's call, management will be making forward-looking statements regarding Immunon's expectations and projections about future events. In general, forward-looking statements can be identified by words such as expects, anticipates, believes, or other similar expressions. These statements are based on current expectations and are subject to a number of risks and uncertainties, including those set forth in the company's periodic filings with the Securities and Exchange Commission. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. I also caution that the content of this conference call is accurate only as of the date of the live broadcast, May 13, 2024. Immunon undertakes no obligation to revise or update comments made during this call, except as required by law. With that said, I would like to turn the call over to Michael Tarduno, Immunon's Executive Chairman. Michael?

Thank you, Kim, and good morning, everyone. And let me also thank you for joining us for this, a particularly important call. I want to start by welcoming Stacey Lindborg, your new chief executive and president, to her first call with the investment community and our supporters. Dr. Lindborg and I are joined by Jeff Church, our chief financial officer, who will provide remarks on our financials, Krishid Anwar, our chief science officer, and Dr. Sebastian Hazard, our chief medical officer, are also on the line. Both will be available for the question and answer period. But first, Dr. Lindborg. For those of you who have read last week's press announcement, you know much of what I'm going to tell you. That Stacey comes to Immunon well-equipped for the task. For many years in our industry, we've seen to that. She accounts among her employment history some of the most storied company's in the pharma and biotech world, including Eli Lilly, Biogen, and most recently, his co-CEO of Brainstorm Cell Therapeutics, where her deep conviction in their clinical stage product led her to present a compelling case to FDA at an adcom for continued development following a Phase III study that missed its primary endpoint. Now, if you followed this adcom as I did, you know that the argument that Stacey made was very impressive. It's clear. that as an experienced biostatistician, Dr. Lindvord's academic focus has provided the regulatory world with innovative approaches to clinical stage product evaluation. Frankly, her career is a history of accomplishment and a record of success that perfectly complements the challenges facing Immunon as we seek to find solutions to some of the most devastating diseases facing modern oncology and medicine. Virtually everyone who has worked with her knows that her skills are not confined, however, to technology and product development. She has a deep and abiding commitment to the people of an organization and to people generally. I witnessed her passion, up front and personally, for an organizational culture of dignity, respect, transparency, and an atmosphere where everyone has a voice. Dr. Stacey Lindborg is someone I have come to know and admire. Her work over the past three years as a member of our board of directors has helped us, and me personally, to evaluate Immunon's priorities and drive our critically important development strategies. I look forward with confidence to Stacey's leadership and the value she will bring to our mission and to you, our shareholders. Stacey, would you like to make a few comments, please?